CA2159116A1 - Composition pharmaceutique servant a la lutte contre certains virus et a la lutte contre des maladies auto-immunes, et methode d'obtention - Google Patents
Composition pharmaceutique servant a la lutte contre certains virus et a la lutte contre des maladies auto-immunes, et methode d'obtentionInfo
- Publication number
- CA2159116A1 CA2159116A1 CA 2159116 CA2159116A CA2159116A1 CA 2159116 A1 CA2159116 A1 CA 2159116A1 CA 2159116 CA2159116 CA 2159116 CA 2159116 A CA2159116 A CA 2159116A CA 2159116 A1 CA2159116 A1 CA 2159116A1
- Authority
- CA
- Canada
- Prior art keywords
- water
- solution
- treatment
- calcium
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- 241000700605 Viruses Species 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 title claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 47
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229960004494 calcium gluconate Drugs 0.000 claims abstract description 23
- 239000004227 calcium gluconate Substances 0.000 claims abstract description 23
- 235000013927 calcium gluconate Nutrition 0.000 claims abstract description 23
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims abstract description 23
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims abstract description 20
- 229940001584 sodium metabisulfite Drugs 0.000 claims abstract description 20
- 235000010262 sodium metabisulphite Nutrition 0.000 claims abstract description 20
- 208000030507 AIDS Diseases 0.000 claims abstract description 19
- 239000011575 calcium Substances 0.000 claims abstract description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960005069 calcium Drugs 0.000 claims abstract description 16
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 16
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 15
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract description 13
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims abstract description 12
- 108010024636 Glutathione Proteins 0.000 claims abstract description 10
- 239000004615 ingredient Substances 0.000 claims abstract description 9
- 229960002885 histidine Drugs 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 159000000000 sodium salts Chemical class 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 239000011734 sodium Substances 0.000 claims abstract description 5
- 229960003330 pentetic acid Drugs 0.000 claims abstract description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract 4
- 229910052708 sodium Inorganic materials 0.000 claims abstract 4
- 239000000243 solution Substances 0.000 claims description 48
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 229910001873 dinitrogen Inorganic materials 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 11
- 201000006417 multiple sclerosis Diseases 0.000 claims description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 208000007514 Herpes zoster Diseases 0.000 claims description 6
- 208000009889 Herpes Simplex Diseases 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 206010036105 Polyneuropathy Diseases 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000005388 borosilicate glass Substances 0.000 claims description 3
- 201000002491 encephalomyelitis Diseases 0.000 claims description 3
- 208000000813 polyradiculoneuropathy Diseases 0.000 claims description 3
- 206010061908 Cranial nerve paralysis Diseases 0.000 claims description 2
- 201000005937 cranial nerve palsy Diseases 0.000 claims description 2
- 239000008215 water for injection Substances 0.000 claims description 2
- IFQSXNOEEPCSLW-DKWTVANSSA-N L-cysteine hydrochloride Chemical compound Cl.SC[C@H](N)C(O)=O IFQSXNOEEPCSLW-DKWTVANSSA-N 0.000 claims 2
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 claims 1
- RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical compound [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 239000003446 ligand Substances 0.000 description 16
- 239000002738 chelating agent Substances 0.000 description 13
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 11
- 230000000840 anti-viral effect Effects 0.000 description 11
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 229960001484 edetic acid Drugs 0.000 description 9
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 229910052725 zinc Inorganic materials 0.000 description 9
- 239000011701 zinc Substances 0.000 description 9
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229910021645 metal ion Inorganic materials 0.000 description 8
- 229960002433 cysteine Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000010255 intramuscular injection Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 5
- 230000011514 reflex Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000004201 L-cysteine Substances 0.000 description 4
- 235000013878 L-cysteine Nutrition 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000000508 neurotrophic effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004970 cd4 cell Anatomy 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 208000004929 Facial Paralysis Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960001305 cysteine hydrochloride Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000000537 electroencephalography Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003573 thiols Chemical group 0.000 description 2
- -1 reduced gluthione Chemical compound 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 101100219382 Caenorhabditis elegans cah-2 gene Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
- 208000037018 Herpes simplex virus encephalitis Diseases 0.000 description 1
- 206010063491 Herpes zoster oticus Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010021283 IIIrd nerve paralysis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000014723 Oculomotor Nerve disease Diseases 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- IOEJYZSZYUROLN-UHFFFAOYSA-M Sodium diethyldithiocarbamate Chemical compound [Na+].CCN(CC)C([S-])=S IOEJYZSZYUROLN-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 238000001056 aerosol solvent extraction system Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000004321 blink reflex Effects 0.000 description 1
- UEAVLBXLOZNDHT-UHFFFAOYSA-K calcium;sodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].[Ca+2].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEAVLBXLOZNDHT-UHFFFAOYSA-K 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- YUANJFKISSSKJB-XRIGFGBMSA-L copper (2S)-2-amino-3-(1H-imidazol-5-yl)propanoate 2-phosphonoacetate Chemical compound P(=O)(O)(O)CC(=O)[O-].N[C@@H](CC1=CNC=N1)C(=O)[O-].[Cu+2] YUANJFKISSSKJB-XRIGFGBMSA-L 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 201000011349 geniculate herpes zoster Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 201000001909 oculomotor nerve paralysis Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000004763 sulfides Chemical group 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RO9300414 | 1993-03-26 | ||
| RO93-00414 | 1993-03-26 | ||
| RO9301803A RO111245B1 (ro) | 1993-12-28 | 1993-12-28 | COMPOZIȚII MEDICAMENTOASE PENTRU TRATAMENTUL IJNOR VIROZE Șl BOLI AUTOIMUNE |
| RO93-01803 | 1993-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2159116A1 true CA2159116A1 (fr) | 1994-10-13 |
Family
ID=26653541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2159116 Abandoned CA2159116A1 (fr) | 1993-03-26 | 1993-12-29 | Composition pharmaceutique servant a la lutte contre certains virus et a la lutte contre des maladies auto-immunes, et methode d'obtention |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0690709A1 (fr) |
| CA (1) | CA2159116A1 (fr) |
| WO (1) | WO1994022438A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4431175A1 (de) * | 1994-09-01 | 1996-04-11 | Medico Pharma Vertriebs Gmbh | Neue, Chelatbildner enthaltende Arzneimittel |
| DE19533477C2 (de) * | 1995-09-12 | 1997-10-23 | Pharma Beratung Dr Klaus Hoffm | Verwendung von Diethylentriaminpentaessigsäure (DTPA) mit immunsuppressiver Wirkung |
| DE19615461C2 (de) * | 1996-04-19 | 1998-05-14 | Detlef Schiele | Mittel zur Ausleitung und Entfernung von Schwermetallspuren aus dem menschlichen Organismus |
| DE19725178A1 (de) * | 1997-06-13 | 1998-12-17 | Sorin Dr Sarzea | Zusammensetzung zur Redoxkontrolle |
| US8420144B2 (en) | 2005-11-09 | 2013-04-16 | Ajinomoto Co., Inc. | Kokumi-imparting agent, method of using, and compositions containing same |
| JP5757674B2 (ja) | 2005-11-09 | 2015-07-29 | 味の素株式会社 | カルシウム受容体活性化剤 |
| PL2175273T3 (pl) * | 2005-11-09 | 2014-02-28 | Ajinomoto Kk | Środek nadający kokumi |
| CN102707070B (zh) * | 2005-11-09 | 2014-11-26 | 味之素株式会社 | 赋予kokumi的作用剂 |
| MX2009012078A (es) | 2007-05-08 | 2009-12-01 | Ajinomoto Kk | Alimento con bajo contenido de grasa. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1110392A (en) * | 1964-09-28 | 1968-04-18 | Yamanouchi Pharma Co Ltd | Composition containing glutathione and an amino acid or amino acids, and salts thereof |
| RO79426B1 (ro) * | 1982-02-23 | 1984-07-30 | Romulus Constantin Dinu | Compozitie medicamentoasa pentru tratamentul unor neuroviroze |
| HU209973B (en) * | 1988-03-09 | 1995-01-30 | Biorex Kutato Fejlesztoe Kft | Process for production of antiviral and immunstimular pharmaceutical composition |
| CH684054A5 (de) * | 1989-11-09 | 1994-07-15 | Asta Medica Ag | Arzneimittel, welche als Wirkstoff Schwefel enthaltende Carbonsäuren enthalten. |
-
1993
- 1993-12-29 WO PCT/RO1993/000006 patent/WO1994022438A1/fr not_active Ceased
- 1993-12-29 CA CA 2159116 patent/CA2159116A1/fr not_active Abandoned
- 1993-12-29 EP EP94904353A patent/EP0690709A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO1994022438A1 (fr) | 1994-10-13 |
| EP0690709A1 (fr) | 1996-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69229975T2 (de) | Pharmazeutische Zusammensetzungen, die ein Anticytokin enthalten | |
| JPH06506690A (ja) | Ｎｍｄａ受容体複合体に媒体されるニューロン障害の阻止方法 | |
| US3888977A (en) | Modified neurotoxin | |
| WO2021128027A1 (fr) | Protéine de fusion taci-fc et son utilisation | |
| EP0346501B1 (fr) | Preparation pharmaceutique pour traiter des etats immunodeficitaires | |
| JPH04504570A (ja) | Ｈｉｖ―感染による疾病の治療 | |
| JPH06506212A (ja) | Ｈｉｖウイルス系疾病、ヘルペス、色素性網膜炎およびマラリアの治療向けリボフラビンの利用 | |
| EP0690709A1 (fr) | Composition pharmaceutique destinee au traitement de certains virus et de certaines maladies auto-immunes, et son procede de preparation | |
| Van Alphen | Acetylcholine synthesis in corneal epithelium | |
| DE3830271A1 (de) | Mittel mit immunsuppressiver wirkung | |
| JP2724711B2 (ja) | 医薬品生成物 | |
| RU2134107C1 (ru) | Препарат "гистохром" для лечения воспалительных заболеваний сетчатки и роговицы глаз | |
| DE60032915T2 (de) | Gallium komplexe von 3-hydroxy-4-pyronen zur behandlung von durch intrazelluläre prokaryoten, dns- und retro-viren verursachten infektionen | |
| DE69833225T2 (de) | Verwendung von histamin um die blutkonzentration des histamins zu erhöhen | |
| US5102902A (en) | Reagents and method for therapeutic treatment of multiple sclerosis | |
| JPS60252416A (ja) | Ｃｄｐコリン組成物 | |
| US4952594A (en) | Reagents and method for therapeutic treatment of multiple sclerosis | |
| EP0137807A1 (fr) | Composition antivirale et son procede d'administration | |
| US4689347A (en) | Medicinal composition for the treatment of certain neuroviruses | |
| WO2012158002A1 (fr) | Préparation médicinale « renessans » à action antibactérienne, anti-ulcère et immunomodulatrice | |
| AT408719B (de) | Mittel zur behandlung von hepatitis c | |
| DE3141970A1 (de) | Arzneimittel zur behandlung der durch den virus der herpes-gruppe erzeugten erkrankungen | |
| US5756477A (en) | Treatment of aids with complex of poly (A). poly (U) | |
| DE69210737T2 (de) | Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen | |
| US6787527B1 (en) | Methods of preventing and treating HIV infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |